title: Should vascular effects of newer treatments be addressed more completely?
authors.affiliation: Division of Cardiology, Department of Medicine, University of California at Los Angeles, 100 Medical Plaza, Suite 630, Los Angeles, CA 90095, USA.
authors.forename: Eric H
authors.initials: EH
authors.lastname: Yang
authors.affiliation: Division of Cardiology, Department of Medicine, University of California at Los Angeles, 100 Medical Plaza, Suite 630, Los Angeles, CA 90095, USA.
authors.forename: Karol E
authors.initials: KE
authors.lastname: Watson
authors.affiliation: Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Joerg
authors.initials: J
authors.lastname: Herrmann
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D000069439:Dasatinib / Q000009:adverse effects; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects; D007093:Imidazoles / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011724:Pyridazines / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib
keywords: cardio-oncology; cardiotoxicity; dasatinib; imatinib resistance; leukemia; nilotinib; peripheral arterial disease; ponatinib; tyrosine kinase inhibitors; vascular toxicity